Compare Kinross Gold Corporation (KGC) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Novartis AG — how do they compare? Kinross Gold Corporation trades at $23.74 (market cap $27.62B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 9.7× Kinross Gold Corporation's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Kinross Gold Corporation for 53 Days and Novartis AG for 82 Days on average.
| KGC | NVS | |
|---|---|---|
Market Cap | $27.62B | $268.57B |
Volume | 6,347,266 | 1,532,573 |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $168.62 |
52-Week Low | $22.47 | $121.80 |
Typical Hold Time | 53 Days | 82 Days |
Enterprise Value | $25.70B | $309.89B |
Dividend Yield | 0.69% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold Corporation (KGC) trades at $23.34, up 0.69% today, with strong fundamentals including a P/E of 8.87 and robust profitability metrics. Recent earnings have consistently beaten expectations, though technical indicators signal bearish momentum. The company reported $7.05B revenue and $2.39B net income for 2025, with cash flow from operations reaching $3.76B. However, production guidance cuts for 2026-2027 have pressured the stock, offset by increased shareholder returns targeting 50% of free cash flow.
KGC presents a mixed outlook: attractive valuation and earnings growth support upside to the $38.80 consensus price target, but near-term risks include operational setbacks at key mines and ongoing legal investigations. The stock's bearish technical trend and rising costs warrant caution, though institutional buying and high analyst buy ratings (58.63%) indicate underlying confidence in long-term value.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
